Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Combination Therapies in Psoriasis
Description
Dr. Erin Bo discusses combination therapies in psoriasis, emphasizing that while monotherapy is ideal when effective, many patients require additional treatments due to incomplete responses or the complexity of their condition. Psoriasis is a chronic disease with various external triggers, and flares complicate management. The presentation highlights the need to consider comorbidities when treating psoriasis, as these can influence treatment efficacy and safety. Dr. Bo outlines key principles for combining therapies, such as maximizing efficacy, minimizing toxicity, and considering different drug mechanisms. Although combination therapy lacks formal approvals for many biologics, it is commonly practiced to enhance outcomes. The talk reviews various combination strategies, such as pairing biologics with methotrexate or small molecule therapeutics like Apramilast, to improve treatment response while being mindful of safety and monitoring. Additionally, the importance of strategically managing half-lives of medications and avoiding drugs with overlapping side effects is stressed. Ultimately, careful consideration of patient-specific factors and comorbidities is essential for optimizing psoriasis treatment through combination therapies.
View moreConclusions
- Monotherapy is the preferred treatment for psoriasis when effective.
- Combination therapies may help maximize treatment response when monotherapy fails.
- It is important to treat psoriasis flares without switching biologic therapies frequently.
- Consideration of comorbidities is crucial in managing psoriasis effectively.
- Therapies should be combined with different but complementary mechanisms of action for better efficacy.
- Monitoring for potential toxicities is essential when using combination therapies.
- There are currently no approved indications for combining biologics with other systemic therapies.
- Adding a systemic therapy to a biologic can improve efficacy and optimize safety profiles.
- Using agents with varying half-lives can enhance disease management.
- Managing psoriasis involves balancing efficacy and safety to achieve optimal patient outcomes.
- Diotallevi et al. Latest combination therapies in psoriasis: Narrative review of the literature. Dermatologic Therapy. 2022; 35
- AbuHilal et al. J Cutan Med Surg 2016; 20(4): 313-316.
- Sacchelli et al. Clin Exo Dermatol. 2019; 44: 243-244
- Nakamura and Koo. Expert Opinion on Drug Safety Volume 19, 2020
- Cather and Crowley. Am J Clin Dermatol (2014) 15: 467-478.
- Gottlieb et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012; 167: 649-657.
- Baranauskaite et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr; 71(4): 541-8.
- Heinecke et al. Combination Use of Ustekinumab With Other Systemic Therapies: A Retrospective Study in a Tertiary Referral Center. J Drugs Dermatol. 2013 Oct; 12(10): 1098-102.
- Ighani et al. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. J Am Acad Dermatol. 2018 Mar; 78(3): 623-626.
- Abu Hilal. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study. J Cutan Med Surg. 2016 Jul; 20(4): 313-6.